Rapid Ebola Test Validated in Field Trials
|
By LabMedica International staff writers Posted on 15 Jul 2015 |
At present, diagnosis of Ebolavirus disease requires transport of venipuncture blood to field biocontainment laboratories for testing by real-time reverse transcription polymerase chain reaction (RT-PCR), resulting in delays that complicate patient care and infection control efforts.
However, RT-PCR is a slow and complex test that comes with attached risks for the health care workers responsible for the collection, transportation and testing of the blood. The complexity and slow turnaround for this diagnostic have been blamed for delaying success in containing the Ebola epidemic.
An international team led by those at the Boston Children's Hospital (MA. USA) performed a rapid diagnostic test on fingerstick blood samples from 106 individuals with suspected Ebolavirus disease presenting at two clinical centers in Sierra Leone during February 2015. They compared the point-of-care rapid diagnostic test results with clinical real-time RT-PCR results (RealStar Filovirus Screen RT-PCR kit 1·0; altona Diagnostics GmbH; Hamburg, Germany) for venipuncture plasma samples tested in a Public Health England field reference laboratory.
The team also performed the rapid diagnostic ReEBOV Antigen Rapid Test (Corgenix; Broomfield, CO, USA), on whole blood and real-time RT-PCR on plasma, on 284 specimens in the reference laboratory, which were submitted to the laboratory for testing from many clinical sites in Sierra Leone. In point-of-care testing, all 28 patients who tested positive for Ebolavirus disease by RT-PCR were also positive by fingerstick rapid diagnostic test and 71 of 77 patients who tested negative by RT-PCR were also negative by the rapid diagnostic test. In laboratory testing, all 45 specimens that tested positive by RT-PCR were also positive by the rapid diagnostic test, and 214 of 232 specimens that tested negative by RT-PCR were also negative by the rapid diagnostic test.
The authors concluded that the ReEBOV rapid diagnostic test had 100% sensitivity and 92% specificity in both point-of-care and reference laboratory testing in this population. With two independent readers, the test detected all patients who were positive for Ebolavirus by altona real-time RT-PCR; however, this benchmark itself had imperfect sensitivity. The study was published on June 26, 2015, in the journal the Lancet.
Related Links:
Boston Children's Hospital
altona Diagnostics GmbH
Corgenix
However, RT-PCR is a slow and complex test that comes with attached risks for the health care workers responsible for the collection, transportation and testing of the blood. The complexity and slow turnaround for this diagnostic have been blamed for delaying success in containing the Ebola epidemic.
An international team led by those at the Boston Children's Hospital (MA. USA) performed a rapid diagnostic test on fingerstick blood samples from 106 individuals with suspected Ebolavirus disease presenting at two clinical centers in Sierra Leone during February 2015. They compared the point-of-care rapid diagnostic test results with clinical real-time RT-PCR results (RealStar Filovirus Screen RT-PCR kit 1·0; altona Diagnostics GmbH; Hamburg, Germany) for venipuncture plasma samples tested in a Public Health England field reference laboratory.
The team also performed the rapid diagnostic ReEBOV Antigen Rapid Test (Corgenix; Broomfield, CO, USA), on whole blood and real-time RT-PCR on plasma, on 284 specimens in the reference laboratory, which were submitted to the laboratory for testing from many clinical sites in Sierra Leone. In point-of-care testing, all 28 patients who tested positive for Ebolavirus disease by RT-PCR were also positive by fingerstick rapid diagnostic test and 71 of 77 patients who tested negative by RT-PCR were also negative by the rapid diagnostic test. In laboratory testing, all 45 specimens that tested positive by RT-PCR were also positive by the rapid diagnostic test, and 214 of 232 specimens that tested negative by RT-PCR were also negative by the rapid diagnostic test.
The authors concluded that the ReEBOV rapid diagnostic test had 100% sensitivity and 92% specificity in both point-of-care and reference laboratory testing in this population. With two independent readers, the test detected all patients who were positive for Ebolavirus by altona real-time RT-PCR; however, this benchmark itself had imperfect sensitivity. The study was published on June 26, 2015, in the journal the Lancet.
Related Links:
Boston Children's Hospital
altona Diagnostics GmbH
Corgenix
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Microbiology News
- Rapid Gastrointestinal PCR Panels Deliver One-Hour Results
- H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention
- Machine Learning Reveals Consistent Gut Microbiome Patterns in Colorectal Cancer
- Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella
- Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
- Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
- Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
- New Protein Targets Support Diagnostics for Louse-Borne Relapsing Fever
- TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy
- Automated Blood Culture System Speeds Detection of Bloodstream Infections
- New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
- Gut Microbiome Signatures Help Identify Risk of IBD Progression
- FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
- New AMR Assay Supports Rapid Infection Control Screening in Hospitals
- Diagnostic Gaps Complicate Bundibugyo Ebola Outbreak Response in Congo
- Study Finds Hidden Mpox Infections May Drive Ongoing Spread
Channels
Clinical Chemistry
view channel
FDA-Approved Test Identifies Low Risk of Large Esophageal Varices in Cirrhosis
Chronic liver disease contributes substantially to mortality, and clinicians routinely screen adults with compensated cirrhosis for varices to prevent bleeding. However, endoscopy is invasive and reso... Read more
Blood Protein Signature Diagnoses Pediatric IBD and Distinguishes Subtypes
Confirming pediatric inflammatory bowel disease (IBD) often requires imaging, endoscopy, and histopathology, prolonging time to diagnosis. Reliable, noninvasive blood tests remain an unmet need in routine... Read moreMolecular Diagnostics
view channel
New Molecular Marker Helps Predict Multiple Myeloma Prognosis
Multiple myeloma is a bone marrow cancer marked by resistance to therapy and frequent relapse, complicating long-term disease control. Better molecular markers are needed to refine risk assessment and... Read more
Blood-Based RNA Biomarker Improves Prediction of Alzheimer’s Onset
Timely identification of patients approaching symptomatic Alzheimer’s disease (AD) remains a major clinical challenge, even as blood-based biomarkers continue to advance. Current assays are highly effective... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read morePathology
view channel
AI Pathology Tool Predicts Immunotherapy Response in Rare Cancers
Immunotherapy has transformed care for select malignancies, yet predicting which patients with rare cancers are most likely to benefit remains challenging. Clinicians often have only limited biomarkers... Read more
Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
Reliable histologic subtyping guides therapy selection in oncology, yet diagnostic workflows grow more complex as whole-slide imaging and artificial intelligence (AI) expand. A persistent obstacle to clinical... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Partnership Integrates Automated DNA Extraction with Single-Molecule Digital PCR
Countable Labs (Palo Alto, CA, USA) and Promega (Madison, WI, USA) have entered a co-marketing agreement that integrates the Promega Maxwell System for nucleic acid extraction with Countable Labs’ Countable... Read more









